Way Forward
startup series
Dr Sarkar discovered a novel method of detection in the year 2011. He tried it on suspected TB patients, and encouraged, by the preliminary results, decided to setup Annweshan SciTech to bring affordable TB diagnosis to the common people.
Over the past two years, Annweshan has generated data on approximately 1800 + samples, going beyond what was required for their BIG project.
dispute resolution. However, their expectations remain high, and they look forward to more support from the incubator to help them get stabilized and develop the product on time.
Asked to comment on their experience with BIRAC, Manikankana mentions,“ While our initial funding support has come from BIRAC, we found the lack of follow-on funding from BIRAC a bit intriguing!” Given, the potential market of a reliable and affordable TB diagnostic in India, the founders now look forward to follow-on funding from other DBT and DST grants along with investor funding, all of which have been elusive uptil now.
Way Forward
The TB diagnostic market size in Brazil, China, India, South Africa was worth approximately $ 480 million in 2013, which is 46 % of the global market($ 1.03bn). The founders say that India’ s market size for the product is 25 % of global requirements. Their revenue expectation by the 4th year( 2021) of marketing is approximately INR 80 crore and INR 149 crore for India and globally respectively.
40 BioVoiceNews | September 2017